These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 30912136)
1. Loss of MCL1 function sensitizes the MDA-MB-231 breast cancer cells to rh-TRAIL by increasing DR4 levels. De Blasio A; Pratelli G; Drago-Ferrante R; Saliba C; Baldacchino S; Grech G; Tesoriere G; Scerri C; Vento R; Di Fiore R J Cell Physiol; 2019 Aug; 234(10):18432-18447. PubMed ID: 30912136 [TBL] [Abstract][Full Text] [Related]
2. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells. Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632 [TBL] [Abstract][Full Text] [Related]
3. Notch inhibition restores TRAIL-mediated apoptosis via AP1-dependent upregulation of DR4 and DR5 TRAIL receptors in MDA-MB-231 breast cancer cells. Portanova P; Notaro A; Pellerito O; Sabella S; Giuliano M; Calvaruso G Int J Oncol; 2013 Jul; 43(1):121-30. PubMed ID: 23686163 [TBL] [Abstract][Full Text] [Related]
4. Tumor Cell-selective Synergism of TRAIL- and ATRA-induced Cytotoxicity in Breast Cancer Cells. Reinhardt A; Liu H; Ma Y; Zhou Y; Zang C; Habbel JP; Possinger K; Eucker J Anticancer Res; 2018 May; 38(5):2669-2682. PubMed ID: 29715087 [TBL] [Abstract][Full Text] [Related]
5. Glutamine deprivation sensitizes human breast cancer MDA-MB-231 cells to TRIAL-mediated apoptosis. Dilshara MG; Jeong JW; Prasad Tharanga Jayasooriya RG; Neelaka Molagoda IM; Lee S; Park SR; Choi YH; Kim GY Biochem Biophys Res Commun; 2017 Apr; 485(2):440-445. PubMed ID: 28202415 [TBL] [Abstract][Full Text] [Related]
6. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism. Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681 [TBL] [Abstract][Full Text] [Related]
7. The expression of TRAIL and its receptors in gastric cancer and the apoptotic effect of rh-TRAIL on SGC7901 cells. Hu JK; Yang K; Li CM; Zhang B; Chen ZX; Chen XZ; Chen JP Oncol Rep; 2009 Mar; 21(3):681-8. PubMed ID: 19212626 [TBL] [Abstract][Full Text] [Related]
8. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628 [TBL] [Abstract][Full Text] [Related]
9. Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening. Garimella SV; Gehlhaus K; Dine JL; Pitt JJ; Grandin M; Chakka S; Nau MM; Caplen NJ; Lipkowitz S Breast Cancer Res; 2014 Apr; 16(2):R41. PubMed ID: 24745479 [TBL] [Abstract][Full Text] [Related]
10. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis. Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956 [TBL] [Abstract][Full Text] [Related]
11. Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5. Di X; Zhang G; Zhang Y; Takeda K; Rivera Rosado LA; Zhang B Oncotarget; 2013 Sep; 4(9):1349-64. PubMed ID: 23988408 [TBL] [Abstract][Full Text] [Related]
12. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Zhang Y; Zhang B Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831 [TBL] [Abstract][Full Text] [Related]
13. Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous TRAIL-induced apoptosis. Aroui S; Brahim S; Hamelin J; De Waard M; Bréard J; Kenani A Apoptosis; 2009 Nov; 14(11):1352-65. PubMed ID: 19731037 [TBL] [Abstract][Full Text] [Related]
14. Piperine enhances the efficacy of TRAIL-based therapy for triple-negative breast cancer cells. Abdelhamed S; Yokoyama S; Refaat A; Ogura K; Yagita H; Awale S; Saiki I Anticancer Res; 2014 Apr; 34(4):1893-9. PubMed ID: 24692724 [TBL] [Abstract][Full Text] [Related]
15. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385 [TBL] [Abstract][Full Text] [Related]
16. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer. Yang J; Li G; Zhang K Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136 [TBL] [Abstract][Full Text] [Related]
17. Gene Expression Alterations Associated with Oleuropein-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells. Messeha SS; Zarmouh NO; Asiri A; Soliman KFA Nutrients; 2020 Dec; 12(12):. PubMed ID: 33297339 [TBL] [Abstract][Full Text] [Related]
18. Oncogenic fusion E2A-HLF sensitizes t(17;19)-positive acute lymphoblastic leukemia to TRAIL-mediated apoptosis by upregulating the expression of death receptors. Zhang X; Inukai T; Hirose K; Akahane K; Kuroda I; Honna-Oshiro H; Kagami K; Goi K; Nakamura K; Kobayashi M; Endo M; Yagita H; Kurosawa H; Thomas Look A; Honda H; Inaba T; Nakazawa S; Sugita K Leukemia; 2012 Dec; 26(12):2483-93. PubMed ID: 22743623 [TBL] [Abstract][Full Text] [Related]
19. Rosmarinic acid-induced apoptosis and cell cycle arrest in triple-negative breast cancer cells. Messeha SS; Zarmouh NO; Asiri A; Soliman KFA Eur J Pharmacol; 2020 Oct; 885():173419. PubMed ID: 32750370 [TBL] [Abstract][Full Text] [Related]
20. Regulation in the targeting of TRAIL receptor 1 to cell surface via GODZ for TRAIL sensitivity in tumor cells. Oh Y; Jeon YJ; Hong GS; Kim I; Woo HN; Jung YK Cell Death Differ; 2012 Jul; 19(7):1196-207. PubMed ID: 22240897 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]